Prediction of response of EGFR tyrosine kinase inhibtors by plasma DNA

Prediction of response of EGFR tyrosine kinase inhibtors by plasma DNA - Prediction of response of EGFR-TKI by plasma DNA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006764

Enrollment

Registered

2011-11-24

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer patients with active EGFR mutations in their tumors

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Active EGFR mutation, 2) Planning of treatment with 1st or 2nd EGFR-TKI or 1st chemotherapy after 1st EGFR-TKI

Exclusion criteria

Exclusion criteria: No exclusion

Design outcomes

Primary

Measure	Time frame
EGFR gene change and heterogeneity by treatment and tumor sites	—

Countries

Japan

Contacts

Public ContactFumio Imamura

Osaka Medical Center for Cancer and Cardiovascular Diseases Department of Thoracic Oncology

imamura-fu@mc.pref.osaka.jp0669721181

Outcome results